Please assess the completion status of the following clinical trial:

Trial Title: Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is informed of the investigational nature of this study and has given written, informed consent in accordance with institutional, local, and national guidelines.~* Males or females ≥ 18 years of age.~* Premenopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice a highly effective method of birth control for at least 4 weeks prior to study drug administration, and must be willing to continue contraception until at least 4 weeks after the last dose of study drug.~* Participant who has received at least 24 weeks of peginesatide dosing in a previous Affymax-sponsored study.~* One hemoglobin value of ≥ 10.0 grams per deciliter (g/dL) in the 4 weeks prior to study drug administration.~Exclusion Criteria:~* Known intolerance to peginesatide or pegylated products.~* History of antibodies to any erythropoiesis stimulating agent (ESA) or history of pure red cell aplasia (PRCA).~* High likelihood of early withdrawal or interruption of the study (e.g., participant suffers from any clinically significant medical disease or condition that may, in the Investigator's opinion, interfere with safety, assessment, or follow-up of the participant)~* Anticipated life expectancy \< 18 months~* Receipt of any ESA other than peginesatide at any time after participant enrollment in the previous Affymax-sponsored study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Maintenance Switch in Dialysis Participants (Type: EXPERIMENTAL): Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study.
- Treatment Initiation in Non-Dialysis Participants (Type: EXPERIMENTAL): Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).